Antitumor Activity of Thalidomide in Refractory Multiple Myeloma

Cited by (1,002)

Items 801–900 of 1,002

1. Identification of antipsychotic drug fluspirilene as a potential anti-glioma stem cell drug
   Yu Hao Dong, Takuya Furuta, Hemragul Sabit, Tomohiro Kitabayashi, Shabierjiang Jiapaer, Masahiko Kobayashi, Yasushi Ino, Tomoki Todo, Lei Teng, Atsushi Hirao et al. · 2017 · Oncotarget
2. New Drugs in Multiple Myeloma
   Chutima Kunacheewa, Robert Zygmunt Orlowski · 2019 · Annual Review of Medicine
3. Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment
   Rushworth, Linda K., Hewit, Kay, Munnings-Tomes, Sophie, Somani, Sukrut, James, Daniel, Shanks, Emma, Dufès, Christine, Straube, Anne, Patel, Rachana, Leung, Hing Y. · 2020 · British Journal of Cancer
4. B-cell non-Hodgkin lymphoma: importance of angiogenesis and antiangiogenic therapy
   Lei Jiang, Nailin Li · 2020 · Angiogenesis
5. New therapies in multiple myeloma
   Francesca Merchionne, Federico Perosa, Franco Dammacco · 2007 · Clinical and Experimental Medicine
6. Progress in haematopoietic stem cell transplantation for multiple myeloma
   Gösta Gahrton, Bo Björkstrand · 2000 · Journal of Internal Medicine
7. Targeting signalling pathways for the treatment of multiple myeloma
   Klaus Podar, Teru Hideshima, Dharminder Chauhan, Kenneth Carl Anderson · 2005 · Expert Opinion on Therapeutic Targets
8. Maintenance therapy in multiple myeloma
   Ronald A. Mihelic, Johnathan Kaufman, Sagar Lonial · 2007 · Leukemia
9. Central Nervous System Complications of Cancer Therapy
   Patrick Yung Wen · 2003 · Humana Press eBooks
10. Thalidomide: a new anticancer drug?
    Massimo Fanelli, Roberta Sarmiento, Domenico Gattuso, Guido Carillio, Barbara Capaccetti, Angelo Vacca, Aldo Maria Roccaro, Giampietro Gasparini · 2003 · Expert Opinion on Investigational Drugs
11. Hematopoietic Cancer and Angiogenesis
    Doménico Ribatti, Claudio Scavelli, Aldo Maria Roccaro, Enrico Crivellato B, Beatrice Nico, Angelo Vacca · 2004 · Stem Cells and Development
12. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation
    JJ Biagi, Linda Mileshkin, AP Grigg, D. Westerman, Henry Miles Prince · 2001 · Bone Marrow Transplantation
13. Advances in oral therapy for multiple myeloma
    Gareth John Morgan, Biju Krishnan, Matthew W. Jenner, Faith E. Davies · 2006 · The Lancet Oncology
14. Thalidomide and Its Derivatives: New Promise for Multiple Myeloma
    Donna Weber · 2003 · Cancer Control
15. Multiple Myeloma
    Seema Singhal, Jayesh Mehta · 2006 · Clinical Journal of the American Society of Nephrology
16. Thalidomide analogs as emerging anti-cancer drugs
    Keith S. Dredge, Angus George Dalgleish, J. Blake Marriott · 2003 · Anti-Cancer Drugs
17. Thalidomide metabolites in mice and patients with multiple myeloma.
    Jun Lu, Brian D. Palmer, Phillip Kestell, Peter Browett, Bruce C. Baguley, George W. Muller, Lai-Ming Ching · 2003 · PubMed
18. A Pilot Study of Antiangiogenic Therapy with Bevacizumab and Thalidomide in Patients with Metastatic Renal Cell Carcinoma
    Dina M. Elaraj, Donald Edward White, Seth M. Steinberg, Leah R. Haworth, Steven A. Rosenberg, James Chih‐Hsin Yang · 2004 · Journal of Immunotherapy
19. New Biological Therapies for Multiple Myeloma
    Alfred L. Garfall · 2023 · Annual Review of Medicine
20. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible
    Monika Martha Engelhardt, Klaus Martin Kortüm, Hartmut Goldschmidt, Maximilian Merz · 2024 · Haematologica
21. Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study
    A. Gunther, P. Baumann, Renate Burger, Christian Kellner, Wolfram Klapper, Ralf Schmidmaier, Martin Gramatzki · 2015 · Haematologica
22. A Review of Angiogenesis and Anti-Angiogenic Therapy in Hematologic Malignancies
    S. Vincent Rajkumar, Ruben A. Mesa, Ayalew Tefferi · 2002 · Stem Cells and Development
23. Targeting angiogenesis for the treatment of sarcoma
    Lakshmi Balasubramanian, Andrew M. Evens · 2006 · Current Opinion in Oncology
24. Thalidomide in multiple myeloma
    Paul Gerard Guy Richardson, Teru Hideshima, Kenneth Carl Anderson · 2002 · Biomedicine & Pharmacotherapy
25. Efficacy and Safety Results with the Combination Therapy of Arsenic Trioxide, Dexamethasone, and Ascorbic Acid in Multiple Myeloma Patients: A Phase 2 Trial
    Rony M. Abou-Jawde, Janice Reed, Megan Kelly, Esteban Walker, Steven Ware Andresen, Rachid Baz, Mary Ann Karam, Mohamad A. Hussein · 2006 · Medical Oncology
26. Newer Therapies for Cutaneous Sarcoidosis
    Robert Phillip Baughman, Elyse E. Lower · 2004 · American Journal of Clinical Dermatology
27. Clinical trials with anti‐angiogenic agents in hematological malignancies
    Medinger, Michael, Mross, Klaus · 2010 · Journal of Angiogenesis Research
28. Emerging therapeutic strategies in glioblastsoma: drug repurposing, mechanisms of resistance, precision medicine, and technological innovations
    Mohamed S. Anwer, Mohammed A. Abdel-Rasol, Wael Mohamed El-Sayed · 2025 · Clinical and Experimental Medicine
29. Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
    Jean‐Luc Harousseau, Martin H. Dreyling · 2009 · Annals of Oncology
30. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)
    Mohamad Mohty, Michel Attal, Gérald Marit, Claude‐Eric Bulabois, Frédéric Garban, Nicole Gratecos, Bernard Rio, Jean‐Paul Vernant, J J Sotto, Jean-Yves Y. Cahn et al. · 2004 · Bone Marrow Transplantation
31. XPO1 is a critical player for bortezomib resistance in multiple myeloma: A quantitative proteomic approach
    Venkatesh Chanukuppa, Debasish Paul, Khushman Taunk, Tathagata Chatterjee, Sanjeevan Sharma, Saravanan Kumar, Manas Kumar Santra, Srikanth Rapole · 2019 · Journal of Proteomics
32. Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
    Ria, Roberto, Melaccio, Assunta, Racanelli, Vito, Vacca, Angelo · 2020 · Journal of Clinical Medicine
33. JunB is a key regulator of multiple myeloma bone marrow angiogenesis
    Fengjuan Fan, Stefano Malvestiti, Sonia Vallet, Judith Lind, José Manuel García-Manteiga, Eugenio Morelli, Qinyue Jiang, Anja Seckinger, Dirk Hose, Hartmut Goldschmidt et al. · 2021 · Leukemia
34. Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma
    Omar S. Al‐Odat, Max Von Suskil, Robert J. Chitren, Weam Othman Elbezanti, Sandeep Kumar Srivastava, Tülin Budak-Alpdoǧan, Subash C. Jonnalagadda, Bharat Bhushan Aggarwal, Manoj Kumar Pandey · 2021 · Frontiers in Pharmacology
35. The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma
    Stefania Ciolli, Franco Leoni, Cinzia Casini, Carla Breschi, Valeria Santini, Alberto Bosi · 2008 · British Journal of Haematology
36. Continuous low-dose cyclophosphamide–prednisone is effective and well tolerated in patients with advanced multiple myeloma
    Okke de Weerdt · 2001 · The Netherlands Journal of Medicine
37. Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma
    Meletios Athanasios Dimopoulos, Vassillis L. Souliotis, Αchilles Anagnostopoulos, C. Bamia, Anastasia G. Pouli, Ioannis Baltadakis, Evangelos Terpos, Soterios Α. Kyrtopoulos, Petros Paul Sfikakis · 2007 · Haematologica
38. Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism
    Henry G. Watson, Yen Lin Chee · 2008 · Blood Reviews
39. Vascularity, Angiogenesis and Angiogenic Factors in Leukemias and Myelodysplastic Syndromes
    Álvaro Aguayo, Francis Joseph Giles, Maher X. Albitar · 2002 · Leukemia & lymphoma/Leukemia and lymphoma
40. Increased Frequency of Venous Thromboembolism with the Combination of Docetaxel and Thalidomide in Patients with Metastatic Androgen‐Independent Prostate Cancer
    McDonald K. Horne, William Douglas Figg, Phil M. Arlen, James L. Gulley, Catherine Parker, Nehal J. Lakhani, Howard L. Parnes, William L. Dahut · 2003 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
41. KGML-xDTD: a knowledge graph–based machine learning framework for drug treatment prediction and mechanism description
    Chunyu Ma, Zhihan Zhou, Han Liu, David Koslicki · 2022 · GigaScience
42. Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials
    Robert Zygmunt Orlowski · 2013 · Seminars in Oncology
43. Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue
    Sung Hee Hwang, Antonina S. Rait, Kathleen F. Pirollo, Qi Zhou, Venkata Mahidhar Yenugonda, Gary M. Chinigo, Milton L. Brown, Esther H. Chang · 2008 · Molecular Cancer Therapeutics
44. New sources of drugs for hematologic malignancies
    Mahadeo A. Sukhai, Paul A. Spagnuolo, Scott James Weir, James M. Kasper, Lavonne Patton, Aaron David Schimmer · 2011 · Blood
45. SPLINTS: small-molecule protein ligand interface stabilizers
    Eric S. Fischer, Eunyoung Park, Michael J. Eck, Nicolas H. Thomä · 2016 · Current Opinion in Structural Biology
46. LC–MS/MS method for simultaneous determination of thalidomide, lenalidomide, cyclophosphamide, bortezomib, dexamethasone and adriamycin in serum of multiple myeloma patients
    Chang Shu, Tianmei Zeng, Shouhong Gao, Tianyi Xia, Lifeng Huang, Feng Zhang, Wansheng Chen · 2016 · Journal of Chromatography B
47. The Gastrointestinal Complications of Oncologic Therapy
    Mehnaz Azra Shafi, Robert S. Bresalier · 2010 · Gastroenterology Clinics of North America
48. Prenatal exposure to environmental factors and congenital limb defects
    Peter Geoffrey Alexander, Karen L. Clark, Rocky S. Tuan · 2016 · Birth Defects Research Part C Embryo Today Reviews
49. Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs
    Shaji Kunnathu Kumar, Noopur S Raje, Teru Hideshima, Kenji Ishitsuka, Aldo Maria Roccaro, N Shiraishi, M Hamasaki, Hiroshi Yasui, Nikhil C. Munshi, Paul Gerard Guy Richardson et al. · 2005 · Leukemia
50. Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization
    Susanne C. Schreiber, Jutta Ackermann, Andreas Obermair, Hannes Kaufmann, Eleonora Urbauer, Katharina Aletaha, Heinz Gisslinger, Andreas Chott, Heinz Paul Huber, Johannes W. Drach · 2000 · British Journal of Haematology
51. Multiple Myeloma
    W. S. Dalton, Peter Leif Bergsagel, Walter Michael Kuehl, Kenneth Carl Anderson, Jean‐Luc Harousseau · 2001 · Hematology
52. Inhibiting Aberrant Signal Transducer and Activator of Transcription Protein Activation with Tetrapodal, Small Molecule Src Homology 2 Domain Binders: Promising Agents against Multiple Myeloma
    Brent D. G. Page, Danielle C. Croucher, Zhihua Li, Sina Haftchenary, Victor Hugo Jimenez-Zepeda, Jennifer M. Atkinson, Paul A. Spagnuolo, Yoong Lim Wong, Robert Colaguori, Andrew M. Lewis et al. · 2013 · Journal of Medicinal Chemistry
53. Thrombotic Complications of Myeloma Therapy
    Jeffrey A. Zonder · 2006 · Hematology
54. Reiterative Survival Analyses of Total Therapy 2 for Multiple Myeloma Elucidate Follow-Up Time Dependency of Prognostic Variables and Treatment Arms
    Bart Barlogie, Elias J. Anaissie, Frits van Rhee, John D. Shaughnessy, Jackie D. Szymonifka, Antje Hoering, Nathan M. Petty, John J. Crowley · 2010 · Journal of Clinical Oncology
55. ESRD due to Multiple Myeloma in the United States, 2001–2010
    Scott A. Reule, Donal J. Sexton, Craig A. Solid, Shu‐Cheng Chen, Robert N. Foley · 2015 · Journal of the American Society of Nephrology
56. Risk factors associated with early mortality in patients with multiple myeloma who were treated upfront with a novel agents containing regimen
    Korean Multiple Myeloma Working Party (KMMWP), Sung‐Hoon Jung, Min-Seok Cho, Hee Kyung Kim, Seok Jin Kim, Kihyun Kım, June‐Won Cheong, Soo‐Jeong Kim, Jin Seok Kim, Jae‐Sook Ahn et al. · 2016 · BMC Cancer
57. Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: A population-based cohort study
    Jing Luo, Joshua J. Gagne, Joan E. Landon, Jerry Avorn, Aaron Seth Kesselheim · 2016 · European Journal of Cancer
58. Etiology and treatment of cough in idiopathic pulmonary fibrosis
    Christine L. Vigeland, Andrew H. Hughes, Maureen R. Horton · 2016 · Respiratory Medicine
59. Drug Repositioning: Concept, Classification, Methodology, and Importance in Rare/Orphans and Neglected Diseases
    Emanuel Almeida Moreira de Oliveira, Karen Luise Lang · 2018 · Journal of Applied Pharmaceutical Science
60. Amyloid deposition in the tongue: clinical and histopathological profile.
    Francesca Angiero, Rossella Seramondi, Sarah Magistro, Rolando Crippa, Stefano Benedicenti, Clara Rizzardi, Giorgio Cattoretti · 2010 · PubMed
61. A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma
    Teru Hideshima · 2008 · Therapeutics and Clinical Risk Management
62. Mechanisms of action and potential therapeutic uses of thalidomide.
    Hamza Mujagić, Bruce Allan Chabner, Zlata Mujagić · 2002 · PubMed
63. Antiangiogenic strategies, compounds, and early clinical results in breast cancer
    Alessandro Morabito, Roberta Sarmiento, Paola Bonginelli, Giampietro Gasparini · 2004 · Critical Reviews in Oncology/Hematology
64. Angiogenesis in chronic myeloproliferative diseases detected by CD34 expression
    Katerina E. Panteli, Νεκταρία Ζαγοριανάκου, Marina Bai, Afroditi Katsaraki, Niki John Agnantis, Konstantinos L. Bourantas · 2004 · European Journal Of Haematology
65. The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma
    J.K Grover, G. Uppal, Vinod Raina · 2002 · Annals of Oncology
66. Low dose velcade, thalidomide and dexamethasone (LD-VTD): An effective regimen for relapsed and refractory multiple myeloma patients
    Stefania Ciolli, F. Leoni, Federica Gigli, Luigi Rigacci, Alberto Bosi · 2005 · Leukemia & lymphoma/Leukemia and lymphoma
67. NF-κ B as a Molecular Target in the Therapy of Pancreatic Carcinoma
    Susanne Sebens, Alexander Arlt, H. Schäfer · 2007 · Springer eBooks
68. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia
    Deborah Ann Thomas, Elihu H. Estey, Francis Joseph Giles, Stefan H Faderl, Jörge E. Cortes, Michael J. Keating, Susan Mary O'Brien, Maher X. Albitar, Hagop M. Kantarjian · 2003 · British Journal of Haematology
69. Arsenic Trioxide in Multiple Myeloma
    Kenneth Carl Anderson, Lawrence Boise, Robert E. Louie, Samuel Waxman · 2002 · The Cancer Journal
70. Phthalimide as a versatile pharmacophore scaffold: Unlocking its diverse biological activities
    Guilherme Fernandes, Juliana Romano Lopes, Jean Leandro dos Santos, Cauê Benito Scarim · 2023 · Drug Development Research
71. Anticancer Properties of a Novel Class of Tetrafluorinated Thalidomide Analogues
    Shaunna Beedie, Cody J. Peer, Steven Pisle, Erin R. Gardner, Christopher B. Mahony, Shelby Barnett, Agnieszka Ambrożak, Michael Gütschow, Cindy H. Chau, Neil Vargesson et al. · 2015 · Molecular Cancer Therapeutics
72. From Anecdote to Targeted Therapy: The Curious Case of Thalidomide in Multiple Myeloma
    Jonathan D. Licht, Jake Shortt, Ricky W. Johnstone · 2014 · Cancer Cell
73. Current therapeutic uses of lenalidomide in multiple myeloma
    Teru Hideshima, Paul Gerard Guy Richardson, Kenneth Carl Anderson · 2006 · Expert Opinion on Investigational Drugs
74. Thalidomide for Erythema Nodosum Leprosum and Other Applications
    Mark C Okafor · 2003 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
75. Novel p97/ VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib‐sensitive and ‐resistant multiple myeloma cells
    Nao Nishimura, Mohamed O. Radwan, Masayuki Amano, Shinya Endo, Eri Fujii, Hironori Hayashi, Shikiko Ueno, Niina Ueno, Hiro Tatetsu, Hiroyuki Hata et al. · 2019 · Cancer Science
76. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis
    Vanessa Piechotta, Tina Jakob, Peter H. Langer, Ina Monsef, Christof Scheid, Lise J Estcourt, Sunday Ocheni, Sebastian Theurich, Kathrin Kuhr, Benjamin Scheckel et al. · 2019 · Cochrane Database of Systematic Reviews
77. A Buchwald–Hartwig Protocol to Enable Rapid Linker Exploration of Cereblon E3‐Ligase PROTACs**
    Thomas G. Hayhow, Rachel E. A. Borrows, C. R. Diène, Gary Fairley, Charlene Fallan, Shaun M. Fillery, James S. Scott, David W. Watson · 2020 · Chemistry - A European Journal
78. Successful treatment of a patient with HIV‐associated multicentric Castleman disease (MCD) with thalidomide
    Christoph P. Jung, Bertold Emmerich, F.-D. Goebel, Johannes Richard Bogner · 2004 · American Journal of Hematology
79. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment
    Wenlin Du, Yutaka Hattori, Akinori Hashiguchi, Kensuke Kondoh, Nobumichi Hozumi, Yasuo Ikeda, Michiie Sakamoto, Junichi Hata, Taketo Yamada · 2004 · Pathology International
80. Consequences of interactions between the bone marrow stroma and myeloma
    Joshua Epstein, Shmuel Yaccoby · 2003 · The Hematology Journal
81. Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in stage I versus stage II-III
    Kathrin Niemöller, Christian Jakob, Ulrike Heider, Ivana Zavrski, Jan Eucker, Olaf Kaufmann, Kurt Possinger, Orhan Sezer · 2003 · Journal of Cancer Research and Clinical Oncology
82. Thalidomide–dexamethasone as primary therapy for advanced multiple myeloma
    Michael L. Wang, Donna M. Weber, Kay B. Delasalle, Raymond Alexanian · 2005 · American Journal of Hematology
83. High-dose therapy and innovative approaches to treatment of multiple myeloma
    Bart Barlogie · 2001 · Seminars in Hematology
84. Drug Discovery Approaches to Target E3 Ligases
    A. Rodríguez-Gimeno, Carles Galdeano · 2024 · ChemBioChem
85. Drug Repositioning in Oncology
    Marissa Bolson Serafin, Angelita Bottega, Taciéli F. da Rosa, Catrine de Souza Machado, Vitória Segabinazzi Foletto, Silvana Silveira Coelho, Augusto Dias da Mota, Rosmari Hörner · 2019 · American Journal of Therapeutics
86. Drug repositioning: A bibliometric analysis
    Guojun Sun, Dashun Dong, Zuojun Dong, Qian Zhang, Hui Fang, Chaojun Wang, Shaoya Zhang, Shuaijun Wu, Yichen Dong, Yuehua Wan · 2022 · Frontiers in Pharmacology
87. A Multicenter Retrospective Analysis of Adverse Events in Korean Patients Using Bortezomib for Multiple Myeloma
    Soo‐Mee Bang, Jae Seung Lee, Sung‐Soo Yoon, Seonyang Park, Chang‐Ki Min, Chun-Choo Kim, Cheolwon Suh, Sang Sohn, Yoo Hong Min, Je-Jung Lee et al. · 2006 · International Journal of Hematology
88. Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide
    Korean Multiple Myeloma Working Party, Youngil Koh, Soo-Mee Bang, Jae Hoon Lee, Hwi‐Joong Yoon, Young-Rok Do, Hun-Mo Ryoo, Nari Lee, Seok Jin Kim, Kihyun Kım et al. · 2009 · Annals of Hematology
89. Eight‐year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1
    Maurizio Zangari, Frits van Rhee, Elias J. Anaissie, Mauricio Pineda‐Roman, Jeff Haessler, John J. Crowley, Bart Barlogie · 2008 · British Journal of Haematology
90. New Approaches to Treatment for Multiple Myeloma: Durable Remission and Quality of Life as Primary Goals
    Brian G.M. Durie · 2005 · Clinical Lymphoma & Myeloma
91. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines, angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome
    Linda Mileshkin, Dirk Hönemann, Peter C Gambell, M Trivett, Yoshihiro Hayakawa, Mark John Smyth, Victoria Beshay, David Ritchie, Paul J. Simmons, Abbie Milner et al. · 2007 · Haematologica
92. Targeted Therapy in Multiple Myeloma
    Wee Joo Chng, Lee Gong Lau, Noorainun Yusof, Benjamin M. F. Mow · 2005 · Cancer Control
93. Thalidomide in the treatment of cancer
    Julian Adlard · 2000 · Anti-Cancer Drugs
94. Early response predicts thalidomide efficiency in patients with advanced multiple myeloma*
    Anders Waage, Peter Gimsing, Gunnar Juliusson, Ingemar Turesson, Nina Gulbrandsen, Tommy Eriksson, Martin Hjorth, Johan Lanng Nielsen, Stig Lenhoff, Jan Westin et al. · 2004 · British Journal of Haematology
95. Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer
    Siow Ming Lee, Lindsay E. James, Tomáš Büchler, M. P. Snee, PA Ellis, Allan K. Hackshaw · 2007 · Lung Cancer
96. Maintenance thalidomide following single cycle autologous peripheral blood stem cell transplant in patients with multiple myeloma
    Firoozeh Sahebi, Ricardo Tomas Spielberger, Neil Martin Kogut, Henry C.H. Fung, Peter Falk, Pablo Miguel Parker, A. Krishnan, R. Rodríguez, Ryotaro Nakamura, Auayporn P. Nademanee et al. · 2006 · Bone Marrow Transplantation
97. Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation.
    Patrizia Tosi, Sonia Ronconi, Elena Zamagni, Claudia Cellini, Tiziana Grafone, Delia Cangini, Stefano Aldo Pileri, Michele Baccarani, Sante Tura, Michèle Cavo · 2001 · PubMed
98. Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant
    Antonio Palumbo, Patrizia Falco, Maria Teresa Ambrosini, Maria Teresa Petrucci, Pellegrino Musto, Tommaso Caravita, Patrizia Pregno, Alessandra Bertola, Federica Cavallo, Giovannino Ciccone et al. · 2005 · European Journal Of Haematology
99. First-line thalidomide–dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma
    A Abdelkefi, Lamia Torjman, Neïla Ben Romdhane, Saloua Ladeb, Halima El Omri, Tarek Ben Othman, M. Elloumi, Hatem Bellaj, Amel Lakhal, Ramzi Jeddi et al. · 2005 · Bone Marrow Transplantation · Retracted
100. Plasma cell leukemia
     Suzanne R. Hayman, Rafaël Fonseca · 2001 · Current Treatment Options in Oncology